Can Investors Excel in 2020 With Exelixis?
Investors looking for an undervalued biotechnology stock that provides long-term profitability should consider adding Exelixis (NASDAQ: EXEL) to their portfolios. Exelixis is a profitable company thanks to the success of its lead cancer drug, Cabometyx, which treats various forms of cancer, including in the kidney, thyroid, and liver.
Cabometyx, a brand name of the compound cabozantinib, is a targeted therapy that focuses on inhibiting an enzyme called tyrosine kinase that plays a role in cell functions, including cell signaling, growth, and division. In cancer cells, these enzymes are often too active or found in high levels, so treatment requires the need for tyrosine kinase inhibitors. Since 2001, there have been more than 20 tyrosine kinase inhibitors approved by the Food and Drug Administration to treat different forms of cancer. How does cabozantinib differentiate?
Image Source: Getty Images
Source Fool.com
